KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of EPS (Weighted Average and Diluted) data on record, last reported at $4.64 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 28.18% year-over-year to $4.64; the TTM value through Dec 2025 reached $15.32, up 836.54%, while the annual FY2025 figure was $15.32, 836.54% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $4.64 in Q4 2025 per VRTX's latest filing, up from $4.2 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $4.64 in Q4 2025 and bottomed at -$13.92 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is $2.45, with a median of $3.4 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 1103.85% in 2022, then plummeted 495.45% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.98 in 2021, then grew by 5.37% to $3.14 in 2022, then rose by 18.15% to $3.71 in 2023, then decreased by 2.43% to $3.62 in 2024, then increased by 28.18% to $4.64 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $4.64 in Q4 2025, $4.2 in Q3 2025, and $3.99 in Q2 2025.